Biomarker Signatures to Track Duchenne Muscular Dystrophy
Official title: Biomarker Signatures for Duchenne Muscular Dystrophy
Funded at State University of Ny,binghamton · NIH-11134768 · Data updated 2026-11-12
A research project aims to identify and validate blood-based biomarkers that can reliably monitor Duchenne muscular dystrophy progression and response to treatment in people who have the condition.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University of Ny,binghamton NIH-funded |
| Lab location | 1 site (Binghamton, United States) |
| Project start | April 1, 2022 |
| Project end | March 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $508,003 |
| NIH project number | 4R33NS119639-04 |
| Project ID | NIH-11134768 on NIH RePORTER |
Who could benefit from this research
✓Could help
Individuals with Duchenne muscular dystrophy who can participate in biomarker studies and related blood testing.
✕Less likely to help
Patients not suitable for blood biomarker studies or without access to participating sites may not benefit directly.
What this research studies
This project focuses on Duchenne muscular dystrophy and uses blood-based biomarkers as potential surrogate tools to track disease changes. Researchers will develop and test precise assays, building on past biomarker work with SomaScan and mass spectrometry. The effort includes a rigorous workflow to translate biomarker findings from the lab into clinical trial settings and patient care, with two phases to establish reliability, specificity, and usefulness in monitoring disease course.
Why it matters
Potential benefit: If successful, patients could benefit from clearer, easier-to-use measures that reflect how the disease is changing or responding to therapy.
How similar studies have gone: Previous biomarker work in Duchenne with SomaScan and mass spectrometry supports the potential for successful biomarker development.
Where this research is happening
-
State University of Ny,binghamton
Binghamton, United States Active
Researchers
- Principal investigator: Hathout, Yetrib — State University of Ny,binghamton
- Study coordinator: Hathout, Yetrib
Related research
Other NIH-funded projects on the same topics.
-
Advancing manufacturing and release testing for a Duchenne gene editing therapy
A project to optimize how a dual-vector AAV gene editing treatment for Duchenne muscular dystrophy is made and tested, so it can move toward clinical use.
-
Understanding why Duchenne Muscular Dystrophy worsens and how to stop it
A research team at USC is studying Duchenne muscular dystrophy to find out why the disease continues to progress and how to interrupt harmful changes in muscle tissue.
-
Stopping steroid-related muscle and bone wasting in Duchenne muscular dystrophy
Researchers are testing ways to protect muscles and bones in people with Duchenne muscular dystrophy who take long-term steroid medicines.
-
MR clues to how nNOS affects energy use and blood flow in Becker and Duchenne muscular dystrophy
This project looks at how advanced MRI tests can track muscle energy and blood flow changes in people with Becker and Duchenne muscular dystrophy as new gene therapies are explored.
-
Digital motor-skill tracking for infants with Duchenne Muscular Dystrophy using wearables
A wearable-sensor project aims to quietly track and quantify how motor skills develop in babies and young boys with Duchenne Muscular Dystrophy.
-
Genetic factors that influence Duchenne Muscular Dystrophy progression
A study to find genes that change how severe Duchenne muscular dystrophy is in boys and young men, using patient data and DNA samples.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.